Multicentric Castleman Disease (MCD) Latest Advances

Effects of Janus kinase inhibition and interleukin 6 inhibition on serum cytokine/chemokine in idiopathic multicentric Castleman disease.

Journal: Drug discoveries & therapeutics

Published: April 01, 2026

CRE26-069: Human Herpesvirus-8 Associated Multicentric Castleman Disease Presenting as Secondary Hemophagocytic Lymphohistiocytosis in Human Immunodeficiency Virus Infection.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

Angiomatous Subtype of Penile Kaposi Sarcoma With Concurrent HIV-Negative Multicentric Castleman Disease: A Case Report.

Journal: International journal of surgical pathology

Published: March 23, 2026

Retraction of: Multicentric Castleman disease presenting with frequent urination.

Journal: Rheumatology (Oxford, England)

Published: March 17, 2026

Interfollicular Plasmacytosis and Hyperplastic Germinal Centers in Idiopathic Multicentric Castleman Disease, Idiopathic Plasmacytic Lymphadenopathy Subtype.

Journal: American journal of hematology

Published: March 04, 2026

Systemic bone destruction as a presentation of idiopathic multicentric Castleman disease.

Journal: British journal of haematology

Published: February 16, 2026

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Journal: Frontiers in oncology

Published: February 16, 2026

Multicentric Castleman disease (MCD) presenting with retiform purpura: A rare dermatologic manifestation of a systemic disease.

Journal: JAAD case reports

Published: February 02, 2026

Concurrent Idiopathic Multicentric Castleman Disease with TAFRO and Sjögren's Syndrome in a Young Patient: A Challenging Diagnostic Overlap.

Journal: European journal of case reports in internal medicine

Published: January 12, 2026

Severe polyneuropathy in HIV-negative human herpesvirus 8-associated multicentric Castleman disease successfully treated with rituximab and liposomal doxorubicin.

Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy

Published: January 12, 2026

Dysregulated lymphocyte localization in idiopathic multicentric Castleman disease.

Journal: bioRxiv : the preprint server for biology

Published: December 25, 2025

Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial.

Journal: Modern rheumatology

Published: December 16, 2025

Multicentric Castleman Disease (MCD) Latest Advances

Find the Latest Research About Multicentric Castleman Disease (MCD)

Effects of Janus kinase inhibition and interleukin 6 inhibition on serum cytokine/chemokine in idiopathic multicentric Castleman disease.

Effects of Janus kinase inhibition and interleukin 6 inhibition on serum cytokine/chemokine in idiopathic multicentric Castleman disease.

CRE26-069: Human Herpesvirus-8 Associated Multicentric Castleman Disease Presenting as Secondary Hemophagocytic Lymphohistiocytosis in Human Immunodeficiency Virus Infection.

CRE26-069: Human Herpesvirus-8 Associated Multicentric Castleman Disease Presenting as Secondary Hemophagocytic Lymphohistiocytosis in Human Immunodeficiency Virus Infection.

Angiomatous Subtype of Penile Kaposi Sarcoma With Concurrent HIV-Negative Multicentric Castleman Disease: A Case Report.

Angiomatous Subtype of Penile Kaposi Sarcoma With Concurrent HIV-Negative Multicentric Castleman Disease: A Case Report.

Retraction of: Multicentric Castleman disease presenting with frequent urination.

Retraction of: Multicentric Castleman disease presenting with frequent urination.

Interfollicular Plasmacytosis and Hyperplastic Germinal Centers in Idiopathic Multicentric Castleman Disease, Idiopathic Plasmacytic Lymphadenopathy Subtype.

Interfollicular Plasmacytosis and Hyperplastic Germinal Centers in Idiopathic Multicentric Castleman Disease, Idiopathic Plasmacytic Lymphadenopathy Subtype.

Systemic bone destruction as a presentation of idiopathic multicentric Castleman disease.

Systemic bone destruction as a presentation of idiopathic multicentric Castleman disease.

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network.

Multicentric Castleman disease (MCD) presenting with retiform purpura: A rare dermatologic manifestation of a systemic disease.

Multicentric Castleman disease (MCD) presenting with retiform purpura: A rare dermatologic manifestation of a systemic disease.

Concurrent Idiopathic Multicentric Castleman Disease with TAFRO and Sjögren's Syndrome in a Young Patient: A Challenging Diagnostic Overlap.

Concurrent Idiopathic Multicentric Castleman Disease with TAFRO and Sjögren's Syndrome in a Young Patient: A Challenging Diagnostic Overlap.

Severe polyneuropathy in HIV-negative human herpesvirus 8-associated multicentric Castleman disease successfully treated with rituximab and liposomal doxorubicin.

Severe polyneuropathy in HIV-negative human herpesvirus 8-associated multicentric Castleman disease successfully treated with rituximab and liposomal doxorubicin.

Dysregulated lymphocyte localization in idiopathic multicentric Castleman disease.

Dysregulated lymphocyte localization in idiopathic multicentric Castleman disease.

Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial.

Long-term safety and efficacy of filgotinib in patients with idiopathic multicentric Castleman disease: 52-week results from a Phase Ib clinical trial.